Piper Sandler Rates Tenax Therapeutics (TENX) buy

Analyst Yasmeen Rahimi keeps a buy rating on Tenax Therapeutics, setting a price target of $50, a 323.37% upside from the current price.

By TradeTexts Research Desk · Published Jun 12, 2026, 9:10 PM EDT · Updated Jun 18, 2026, 11:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Piper Sandler rated Tenax Therapeutics, Inc. ($TENX) "buy" with a $50 price target on June 12, 2026.

Since the rating, $TENX is up 6.7% after 1 week, up 39.2% after 1 month and down 88.2% to date (from the $11.48 close on Jun 12, 2026).

TENX Tenax Therapeutics, Inc.

$1.36 -87.69% year to date

Daily close · Oct 16, 2026

Key Points

Piper Sandler reiterated its buy rating on Tenax Therapeutics, Inc. (NASDAQ: TENX) and set a price target of $50.00 on June 12, 2026.
The stock is currently trading at $11.81, significantly lower than the target, suggesting potential upside.
The average price target from analysts stands at $12.56, with nine analysts offering opinions on Tenax.

Get $TENX trade alerts by text

We text you when insiders, Congress or big funds trade $TENX. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Tenax Therapeutics, Inc. alert may contain errors. Disclosures

Piper Sandler's Buy Rating on Tenax Therapeutics

Piper Sandler has reiterated its buy rating on Tenax Therapeutics, Inc. (NASDAQ: TENX) with a price target of $50.00 as of June 12, 2026. This recommendation comes as the stock trades at $11.81, indicating a substantial gap between the current price and the analyst's target.

Analysts Set New Price Targets

While Piper Sandler maintains its bullish stance, other analysts have recently downgraded their ratings on Tenax. For example, Guggenheim downgraded its rating to Neutral on August 31, 2026. Chardan Capital also downgraded its rating to Neutral on August 11, 2026, while Canaccord Genuity and Guggenheim maintained their buy ratings but lowered their targets significantly to $4.00. This mixed feedback from analysts shows a divergence in opinions on Tenax's prospects, with some remaining optimistic while others express caution.

Stock Performance Context

Currently, Tenax Therapeutics is trading at $11.81, well below its 52-week high of $19.40. The stock's performance has been volatile, with significant fluctuations over the past year. This trading level could suggest that the market may not fully reflect the potential upside indicated by Piper Sandler's target.

12-month forecast

$TENX price target

Tenax Therapeutics, Inc. daily closes and this analyst's $50 target. Not advice.

What Tenax Therapeutics, Inc. Does

Tenax Therapeutics, Inc., based in Chapel Hill, North Carolina, focuses on developing therapies for cardiopulmonary diseases. The company is working on several product candidates that have shown promise in clinical trials, which adds to the interest from analysts and investors alike.

What to Watch at Tenax Therapeutics, Inc.

Looking ahead, investors should keep an eye on Tenax's upcoming earnings report scheduled for August 11, 2025. As always, analysts' ratings and targets are based on past performance and may not represent future results, so it’s essential to stay updated with the latest news and filings.